NO334273B1 - Rekombinant poxvirus, samt anvendelse derav, vaksine, farmasøytisk sammensetning, celle, fremgangsmåte for generering av et rekombinant poxvirus, sett, DNA-sekvens og anvendelse derav - Google Patents
Rekombinant poxvirus, samt anvendelse derav, vaksine, farmasøytisk sammensetning, celle, fremgangsmåte for generering av et rekombinant poxvirus, sett, DNA-sekvens og anvendelse derav Download PDFInfo
- Publication number
- NO334273B1 NO334273B1 NO20044940A NO20044940A NO334273B1 NO 334273 B1 NO334273 B1 NO 334273B1 NO 20044940 A NO20044940 A NO 20044940A NO 20044940 A NO20044940 A NO 20044940A NO 334273 B1 NO334273 B1 NO 334273B1
- Authority
- NO
- Norway
- Prior art keywords
- genes
- recombinant
- virus
- recombinant poxvirus
- poxvirus
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 239000013598 vector Substances 0.000 claims abstract description 87
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 167
- 241000700605 Viruses Species 0.000 claims description 125
- 238000003780 insertion Methods 0.000 claims description 113
- 230000037431 insertion Effects 0.000 claims description 113
- 210000004027 cell Anatomy 0.000 claims description 67
- 241000725619 Dengue virus Species 0.000 claims description 53
- 238000012217 deletion Methods 0.000 claims description 48
- 230000037430 deletion Effects 0.000 claims description 48
- 230000003612 virological effect Effects 0.000 claims description 29
- 241000700618 Vaccinia virus Species 0.000 claims description 28
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 10
- 241000710831 Flavivirus Species 0.000 claims description 9
- 230000008105 immune reaction Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 6
- 208000007089 vaccinia Diseases 0.000 claims description 6
- 210000004102 animal cell Anatomy 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000010354 integration Effects 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract description 14
- 230000028993 immune response Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 241000700647 Variola virus Species 0.000 description 72
- 206010072219 Mevalonic aciduria Diseases 0.000 description 44
- 208000015181 infectious disease Diseases 0.000 description 36
- 108020004414 DNA Proteins 0.000 description 27
- 239000013612 plasmid Substances 0.000 description 26
- 206010012310 Dengue fever Diseases 0.000 description 20
- 239000012634 fragment Substances 0.000 description 20
- 230000006798 recombination Effects 0.000 description 18
- 238000000746 purification Methods 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 101150064860 PRM gene Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 208000025729 dengue disease Diseases 0.000 description 14
- 238000005215 recombination Methods 0.000 description 14
- 238000002255 vaccination Methods 0.000 description 14
- 108700008625 Reporter Genes Proteins 0.000 description 12
- 238000010367 cloning Methods 0.000 description 12
- 230000006801 homologous recombination Effects 0.000 description 12
- 238000002744 homologous recombination Methods 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 239000013600 plasmid vector Substances 0.000 description 11
- 208000001490 Dengue Diseases 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 229930193140 Neomycin Natural products 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 229940031348 multivalent vaccine Drugs 0.000 description 9
- 229960004927 neomycin Drugs 0.000 description 9
- 208000035473 Communicable disease Diseases 0.000 description 8
- 108091029795 Intergenic region Proteins 0.000 description 8
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 238000002944 PCR assay Methods 0.000 description 6
- 208000009714 Severe Dengue Diseases 0.000 description 6
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000710842 Japanese encephalitis virus Species 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000255925 Diptera Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101150062179 II gene Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 241000710772 Yellow fever virus Species 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 108091005948 blue fluorescent proteins Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 230000017613 viral reproduction Effects 0.000 description 3
- 229940051021 yellow-fever virus Drugs 0.000 description 3
- 201000006082 Chickenpox Diseases 0.000 description 2
- 241000700628 Chordopoxvirinae Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 241000700626 Cowpox virus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000700625 Poxviridae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 201000003740 cowpox Diseases 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241001137864 Camelpox virus Species 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000710815 Dengue virus 2 Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000725630 Ectromelia virus Species 0.000 description 1
- 101000686824 Enterobacteria phage N4 Virion DNA-directed RNA polymerase Proteins 0.000 description 1
- 101001095863 Enterobacteria phage T4 RNA ligase 1 Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000700572 Entomopoxvirinae Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101000644628 Escherichia phage Mu Tail fiber assembly protein U Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241001112691 Goatpox virus Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000700627 Monkeypox virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241001569977 Penguinpox virus Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000223801 Plasmodium knowlesi Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000700665 Sheeppox virus Species 0.000 description 1
- 101710152205 Sporozoite antigen Proteins 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 241000700565 Swinepox virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 201000005332 contagious pustular dermatitis Diseases 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 101150111412 npt gene Proteins 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- -1 preferably C Proteins 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200753 | 2002-05-16 | ||
| DKPA200200752 | 2002-05-16 | ||
| PCT/EP2003/005047 WO2003097846A1 (en) | 2002-05-16 | 2003-05-14 | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20044940L NO20044940L (no) | 2004-11-12 |
| NO334273B1 true NO334273B1 (no) | 2014-01-27 |
Family
ID=29551228
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20044940A NO334273B1 (no) | 2002-05-16 | 2004-11-12 | Rekombinant poxvirus, samt anvendelse derav, vaksine, farmasøytisk sammensetning, celle, fremgangsmåte for generering av et rekombinant poxvirus, sett, DNA-sekvens og anvendelse derav |
| NO20045480A NO336489B1 (no) | 2002-05-16 | 2004-12-16 | Rekombinant modifisert Vaccinia Ankaravirus (MVA), anvendelse derav for fremstilling av medikament og/eller vaksine, vaksine, farmasøytisk sammensetning omfattende nevnte MVA, fremgangsmåte for å introdusere DNA-sekvens i en celle, celle, plasmidvektor, fremgangsmåte for å fremstille MVA, DNA sekvens, anvendelse av plasmidvektor samt anvendelse av DNA. |
| NO20111324A NO20111324A1 (no) | 2002-05-16 | 2011-09-29 | Rekombinant MVA-virus |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045480A NO336489B1 (no) | 2002-05-16 | 2004-12-16 | Rekombinant modifisert Vaccinia Ankaravirus (MVA), anvendelse derav for fremstilling av medikament og/eller vaksine, vaksine, farmasøytisk sammensetning omfattende nevnte MVA, fremgangsmåte for å introdusere DNA-sekvens i en celle, celle, plasmidvektor, fremgangsmåte for å fremstille MVA, DNA sekvens, anvendelse av plasmidvektor samt anvendelse av DNA. |
| NO20111324A NO20111324A1 (no) | 2002-05-16 | 2011-09-29 | Rekombinant MVA-virus |
Country Status (22)
| Country | Link |
|---|---|
| US (14) | US7550147B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP1407033B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP4895505B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR101005630B1 (cg-RX-API-DMAC7.html) |
| CN (6) | CN101831411A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE315660T1 (cg-RX-API-DMAC7.html) |
| AU (4) | AU2003236646B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR0310051A (cg-RX-API-DMAC7.html) |
| CA (3) | CA2481521C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60303218T2 (cg-RX-API-DMAC7.html) |
| DK (2) | DK1506301T3 (cg-RX-API-DMAC7.html) |
| EA (3) | EA012160B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2256776T3 (cg-RX-API-DMAC7.html) |
| IL (4) | IL164177A0 (cg-RX-API-DMAC7.html) |
| MX (2) | MXPA04011194A (cg-RX-API-DMAC7.html) |
| NO (3) | NO334273B1 (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ536501A (cg-RX-API-DMAC7.html) |
| PL (2) | PL216760B1 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1407033E (cg-RX-API-DMAC7.html) |
| SI (1) | SI1407033T1 (cg-RX-API-DMAC7.html) |
| UA (1) | UA82479C2 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2003097845A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4101327C1 (cg-RX-API-DMAC7.html) * | 1991-01-18 | 1991-10-24 | Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De | |
| NZ524661A (en) * | 2000-11-23 | 2005-03-24 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
| NZ536592A (en) * | 2002-04-19 | 2007-01-26 | Bavarian Nordic As | Modified vaccinia virus ankara for the vaccination of neonates |
| EP1407033B1 (en) | 2002-05-16 | 2006-01-11 | Bavarian Nordic A/S | Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva) |
| US7501127B2 (en) * | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| HK1080507B (zh) * | 2002-09-05 | 2011-10-07 | 巴法里安诺迪克有限公司 | 在无血清条件下培养原代细胞和扩增病毒的方法 |
| JP5052893B2 (ja) * | 2003-02-20 | 2012-10-17 | アメリカ合衆国 | ポックスベクターにおける新規の挿入部位 |
| GB2402391A (en) * | 2003-06-04 | 2004-12-08 | Oxxon Pharmaccines Ltd | Fowlpox recombinant genome |
| EP1807508A4 (en) * | 2004-11-05 | 2008-03-12 | Us Gov Health & Human Serv | METHODS FOR PREPARING CELLS AND VIRUSES |
| DK1855720T4 (da) | 2005-02-23 | 2023-07-24 | Bavarian Nordic As | Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer |
| CA2651456A1 (en) * | 2006-05-19 | 2007-11-29 | Glycofi, Inc. | Recombinant vectors |
| US9133478B2 (en) | 2006-08-25 | 2015-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes |
| US8052968B2 (en) * | 2006-10-16 | 2011-11-08 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| US8440202B2 (en) * | 2006-11-09 | 2013-05-14 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using the prime-boost approach |
| WO2008127307A2 (en) * | 2006-11-09 | 2008-10-23 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using prime-boost approach |
| AU2008209759B2 (en) * | 2007-01-30 | 2013-03-21 | Transgene S.A. | Papillomavirus E2 polypeptide used for vaccination |
| US8268327B2 (en) | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
| US8337859B2 (en) * | 2007-05-15 | 2012-12-25 | Transgene S.A. | Vectors for multiple gene expression |
| TW200907058A (en) * | 2007-05-30 | 2009-02-16 | Wyeth Corp | Raccoon poxvirus expressing rabies glycoproteins |
| AU2008260593A1 (en) * | 2007-05-30 | 2008-12-11 | Wyeth | Raccoon poxvirus expressing genes of feline antigens |
| NZ584042A (en) * | 2007-10-18 | 2012-09-28 | Bn Immunotherapeutics Inc | Use of mva to treat prostate cancer |
| US20110052627A1 (en) * | 2008-06-20 | 2011-03-03 | Paul Chaplin | Recombinant modified vaccinia virus measles vaccine |
| KR100894430B1 (ko) * | 2008-11-11 | 2009-04-22 | 시스템디엔디(주) | 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법 |
| EA024749B1 (ru) | 2008-11-21 | 2016-10-31 | Бавариан Нордик А/С | Экспрессионный вектор со сниженным уровнем внутримолекулярной рекомбинации, содержащий гомологичные или гетерологичные нуклеотидные последовательности |
| US8580276B2 (en) | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| KR20120093941A (ko) | 2009-10-08 | 2012-08-23 | 버베리안 노딕 에이/에스 | 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성 |
| CA2777744C (en) | 2009-10-16 | 2019-09-24 | Bernard Moss | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
| US20110159031A1 (en) * | 2009-12-22 | 2011-06-30 | Baxter International Inc. | Vaccine to Influenza A Virus |
| US20130115234A1 (en) * | 2010-03-26 | 2013-05-09 | Emergent Product Development Gaithersburg,Inc. | Ectodomains of Influenza Matrix 2 Protein, Expression System, and Uses Thereof |
| NZ603620A (en) | 2010-07-20 | 2015-01-30 | Bavarian Nordic As | Method for harvesting expression products |
| EP2618840A2 (en) * | 2010-09-23 | 2013-07-31 | Baxter International Inc. | Recombinant viral vectors and methods for inducing an immune response to yellow fever virus |
| US9173933B2 (en) | 2010-10-15 | 2015-11-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara influenza vaccine |
| ES2733211T3 (es) | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| WO2013083254A1 (en) | 2011-12-09 | 2013-06-13 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| US20150150963A1 (en) | 2012-06-05 | 2015-06-04 | The Australian National University | Vaccination with interleukin-4 antagonists |
| CA2879915C (en) | 2012-08-01 | 2022-07-05 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
| JP2016502507A (ja) | 2012-10-19 | 2016-01-28 | バヴァリアン・ノルディック・インコーポレイテッド | 癌治療のための組成物および方法 |
| DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
| WO2014138824A1 (en) * | 2013-03-15 | 2014-09-18 | Sementis Limited | Immune modulation |
| WO2014139587A1 (en) * | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| KR101623498B1 (ko) | 2014-10-16 | 2016-05-24 | 대한민국 | 약독화 백시니아 바이러스주 kvac１０３ |
| KR101645642B1 (ko) | 2014-10-16 | 2016-08-11 | 대한민국 | Kvac１０３ 유래의 재조합 백시니아 바이러스 |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| EP3283088A4 (en) | 2015-04-17 | 2018-10-24 | Memorial Sloan-Kettering Cancer Center | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |
| KR20160140075A (ko) * | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
| AU2016278806A1 (en) | 2015-06-15 | 2017-12-14 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| CN106591361A (zh) * | 2015-10-20 | 2017-04-26 | 钱文斌 | 一种重组痘溶瘤病毒及其构建方法和应用 |
| CA3011014A1 (en) * | 2016-01-08 | 2017-07-13 | Harriet Robinson | Compositions and methods for generating an immune response to a tumor associated antigen |
| HUE059343T2 (hu) | 2016-01-29 | 2022-11-28 | Bavarian Nordic As | Rekombináns, módosított Ankara Vaccinia vírus (MVA) és ló encephalitis vírus oltóanyag |
| BR112018015696A2 (pt) * | 2016-02-03 | 2018-12-26 | Geovax Inc | composições e métodos para gerar uma resposta imune para um flavivírus |
| CA3015650A1 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| EP3419662A4 (en) | 2016-02-25 | 2019-09-18 | Memorial Sloan Kettering Cancer Center | HUMAN FLT3L EXPRESSIVE RECOMBINANT MVA OR MVADELE3L AND USE THEREOF AS IMMUNOTHERAPEUTICS AGAINST SOLID TUMORS |
| EP3452087A1 (en) | 2016-05-02 | 2019-03-13 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv vaccine combinations |
| MX2019001919A (es) * | 2016-08-19 | 2019-09-04 | Sementis Ltd | Vacunas virales. |
| US20200024610A1 (en) * | 2016-09-30 | 2020-01-23 | Monsanto Technology Llc | Method for selecting target sites for site-specific genome modification in plants |
| EP3621646A4 (en) | 2017-05-12 | 2021-06-02 | Memorial Sloan Kettering Cancer Center | USEFUL VACCINE VIRUS MUTANTS FOR ANTI-CANCER IMMUNOTHERAPY |
| CN110958887B (zh) * | 2017-06-15 | 2023-10-31 | 扬森疫苗与预防公司 | 编码hiv抗原的痘病毒载体及其使用方法 |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| EP3790579A4 (en) * | 2018-05-11 | 2022-06-15 | City of Hope | Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof |
| EP3790578A4 (en) | 2018-05-11 | 2022-04-06 | City of Hope | Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof |
| BR112021004692A2 (pt) | 2018-09-15 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | poxvírus recombinantes para imunoterapia de câncer |
| CN111979204B (zh) * | 2019-05-24 | 2023-10-13 | 杭州功楚生物科技有限公司 | 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途 |
| CA3161633A1 (en) | 2019-11-14 | 2021-05-20 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| EP3842065A1 (en) * | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| US20210299245A1 (en) * | 2020-03-31 | 2021-09-30 | Sementis Limited | Attenuated poxvirus vector based vaccine for protection against covid-19 |
| CN117177763A (zh) | 2021-02-02 | 2023-12-05 | 吉奥瓦科斯公司 | 用于增强疫苗接种期间的t细胞启动的病毒构建体 |
| WO2024011250A1 (en) | 2022-07-08 | 2024-01-11 | Viromissile, Inc. | Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| JPH0795956B2 (ja) * | 1986-09-22 | 1995-10-18 | 京都大学長 | ポックスウイルス由来発現制御領域 |
| US5093258A (en) * | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| US5651972A (en) | 1989-04-21 | 1997-07-29 | University Of Florida Research Foundation, Inc. | Use of recombinant swine poxvirus as a live vaccine vector |
| US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
| MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US6893845B1 (en) * | 1990-09-28 | 2005-05-17 | Applied Molecular Evolution, Inc. | Surface expression libraries of heteromeric receptors |
| JP3602530B2 (ja) * | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
| BE1004877A3 (fr) * | 1991-05-27 | 1993-02-16 | Solvay | Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus. |
| FR2679249B1 (fr) * | 1991-07-15 | 1993-11-26 | Centre Nal Recherc Scientifique | Souches de levure avec integration stable de genes heterologues. |
| JPH06509235A (ja) | 1991-07-26 | 1994-10-20 | ヴァイロジェネティクス コーポレイション | 伝染性ファブリキウス嚢病ウイルス組換えポックスウイルスワクチン |
| DE69133333T2 (de) * | 1991-08-26 | 2004-07-29 | Baxter Healthcare S.A. | Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken |
| EP0561034B1 (en) * | 1991-08-26 | 1999-06-09 | IMMUNO Aktiengesellschaft | Direct molecular cloning of a modified chordopox virus genome |
| US5676950A (en) | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| EP0753581A1 (en) * | 1995-07-10 | 1997-01-15 | Immuno Ag | Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines |
| DE19629828A1 (de) * | 1996-07-24 | 1998-01-29 | Bayer Ag | Carbanilide |
| AU4556597A (en) * | 1996-09-24 | 1998-04-17 | Bavarian Nordic Research Institute A/S | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines |
| AUPP380598A0 (en) * | 1998-05-29 | 1998-06-25 | Commonwealth Scientific And Industrial Research Organisation | Genetically manipulated entomopoxvirus |
| US6252871B1 (en) | 1998-07-01 | 2001-06-26 | Powerwave Technologies, Inc. | Switchable combiner/splitter |
| US20040265324A1 (en) * | 1999-03-23 | 2004-12-30 | Cardosa Mary Jane | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines |
| WO2000073476A1 (en) * | 1999-05-28 | 2000-12-07 | Gsf Forschungszentrum Für Umwelt Und Gesundheit Gmbh | Vector for integration of heterologous sequences into poxviral genomes |
| BR0109158A (pt) * | 2000-03-14 | 2003-04-22 | Anton Mayr | Cepa alterada do vìrus de varìola bovina de ankara (mva) |
| CA2341356C (en) * | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| CN1250731C (zh) * | 2000-08-29 | 2006-04-12 | 惠氏控股公司 | 正链rna病毒复制子颗粒的包装 |
| NZ524661A (en) * | 2000-11-23 | 2005-03-24 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
| EP1407033B1 (en) * | 2002-05-16 | 2006-01-11 | Bavarian Nordic A/S | Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva) |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| KR20050083839A (ko) * | 2002-11-25 | 2005-08-26 | 버베리안 노딕 에이/에스 | 두개 이상의 우두 ａｔｉ 프로모터를 포함하는 재조합폭스바이러스 |
-
2003
- 2003-05-14 EP EP20030752741 patent/EP1407033B1/en not_active Expired - Lifetime
- 2003-05-14 CN CN200910208520A patent/CN101831411A/zh active Pending
- 2003-05-14 JP JP2004506500A patent/JP4895505B2/ja not_active Expired - Lifetime
- 2003-05-14 DE DE2003603218 patent/DE60303218T2/de not_active Expired - Lifetime
- 2003-05-14 NZ NZ536501A patent/NZ536501A/en not_active IP Right Cessation
- 2003-05-14 CN CN2011100588236A patent/CN102199628A/zh active Pending
- 2003-05-14 WO PCT/EP2003/005045 patent/WO2003097845A1/en not_active Ceased
- 2003-05-14 PL PL372093A patent/PL216760B1/pl unknown
- 2003-05-14 CN CN2012101928085A patent/CN102703393A/zh active Pending
- 2003-05-14 US US10/514,761 patent/US7550147B2/en not_active Expired - Lifetime
- 2003-05-14 PT PT03752741T patent/PT1407033E/pt unknown
- 2003-05-14 DK DK03735384T patent/DK1506301T3/da active
- 2003-05-14 EP EP10008120.7A patent/EP2253709B1/en not_active Expired - Lifetime
- 2003-05-14 KR KR1020047018293A patent/KR101005630B1/ko not_active Expired - Lifetime
- 2003-05-14 CA CA2481521A patent/CA2481521C/en not_active Expired - Lifetime
- 2003-05-14 JP JP2004506501A patent/JP4693092B2/ja not_active Expired - Lifetime
- 2003-05-14 IL IL16417703A patent/IL164177A0/xx active IP Right Grant
- 2003-05-14 CA CA 2812019 patent/CA2812019A1/en not_active Abandoned
- 2003-05-14 KR KR1020107021891A patent/KR101138067B1/ko not_active Expired - Lifetime
- 2003-05-14 PL PL372088A patent/PL218318B1/pl unknown
- 2003-05-14 KR KR1020047018165A patent/KR101041691B1/ko not_active Expired - Lifetime
- 2003-05-14 BR BR0310051A patent/BR0310051A/pt not_active IP Right Cessation
- 2003-05-14 CN CN2012101926963A patent/CN102719408A/zh active Pending
- 2003-05-14 WO PCT/EP2003/005047 patent/WO2003097846A1/en not_active Ceased
- 2003-05-14 AT AT03752741T patent/ATE315660T1/de active
- 2003-05-14 EA EA200401506A patent/EA012160B1/ru not_active IP Right Cessation
- 2003-05-14 MX MXPA04011194A patent/MXPA04011194A/es active IP Right Grant
- 2003-05-14 US US10/510,189 patent/US7338662B2/en not_active Expired - Lifetime
- 2003-05-14 AU AU2003236646A patent/AU2003236646B2/en not_active Expired
- 2003-05-14 IL IL16417203A patent/IL164172A0/xx unknown
- 2003-05-14 MX MXPA04010713A patent/MXPA04010713A/es active IP Right Grant
- 2003-05-14 NZ NZ536502A patent/NZ536502A/en not_active IP Right Cessation
- 2003-05-14 CN CN038111063A patent/CN1653183B/zh not_active Expired - Lifetime
- 2003-05-14 BR BRPI0311178A patent/BRPI0311178B8/pt not_active IP Right Cessation
- 2003-05-14 ES ES03752741T patent/ES2256776T3/es not_active Expired - Lifetime
- 2003-05-14 EA EA200900180A patent/EA020230B1/ru not_active IP Right Cessation
- 2003-05-14 CA CA2481799A patent/CA2481799C/en not_active Expired - Lifetime
- 2003-05-14 CN CNB038111225A patent/CN100494388C/zh not_active Expired - Lifetime
- 2003-05-14 EA EA200401507A patent/EA007811B1/ru not_active IP Right Cessation
- 2003-05-14 DK DK03752741T patent/DK1407033T3/da active
- 2003-05-14 KR KR1020117031095A patent/KR20120002627A/ko not_active Withdrawn
- 2003-05-14 UA UA20041109409A patent/UA82479C2/uk unknown
- 2003-05-14 SI SI200330215T patent/SI1407033T1/sl unknown
- 2003-05-14 AU AU2003242540A patent/AU2003242540A1/en not_active Abandoned
- 2003-05-14 EP EP20030735384 patent/EP1506301B1/en not_active Expired - Lifetime
-
2004
- 2004-11-12 NO NO20044940A patent/NO334273B1/no not_active IP Right Cessation
- 2004-12-16 NO NO20045480A patent/NO336489B1/no not_active IP Right Cessation
-
2007
- 2007-11-15 US US11/985,510 patent/US9109233B2/en active Active
-
2008
- 2008-07-28 IL IL193087A patent/IL193087A/en active IP Right Grant
- 2008-07-28 IL IL19308808A patent/IL193088A/en active IP Right Grant
- 2008-12-09 AU AU2008255213A patent/AU2008255213B2/en not_active Expired
- 2008-12-19 US US12/339,743 patent/US20100173388A1/en not_active Abandoned
-
2009
- 2009-02-03 AU AU2009200380A patent/AU2009200380C1/en not_active Expired
- 2009-05-19 US US12/468,120 patent/US7964374B2/en not_active Expired - Lifetime
- 2009-05-19 US US12/468,127 patent/US8034354B2/en not_active Expired - Lifetime
-
2010
- 2010-08-05 JP JP2010176511A patent/JP2011004755A/ja active Pending
- 2010-08-05 JP JP2010176512A patent/JP5777199B2/ja not_active Expired - Lifetime
- 2010-09-30 US US12/894,589 patent/US20110053260A1/en not_active Abandoned
- 2010-09-30 US US12/894,550 patent/US20110053259A1/en not_active Abandoned
-
2011
- 2011-04-15 US US13/087,649 patent/US8309326B2/en not_active Expired - Fee Related
- 2011-04-15 US US13/087,715 patent/US8288125B2/en not_active Expired - Fee Related
- 2011-09-15 US US13/233,329 patent/US8414900B2/en not_active Expired - Fee Related
- 2011-09-16 US US13/234,230 patent/US8435543B2/en not_active Expired - Fee Related
- 2011-09-29 NO NO20111324A patent/NO20111324A1/no not_active Application Discontinuation
-
2012
- 2012-02-13 US US13/371,580 patent/US20120178157A1/en not_active Abandoned
-
2013
- 2013-05-02 US US13/886,093 patent/US8741308B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO334273B1 (no) | Rekombinant poxvirus, samt anvendelse derav, vaksine, farmasøytisk sammensetning, celle, fremgangsmåte for generering av et rekombinant poxvirus, sett, DNA-sekvens og anvendelse derav | |
| US9133480B2 (en) | Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites | |
| NO337867B1 (no) | Modifisert Vaccinia Ankara virusstamme MVA-BN og derivater derav, fremgangsmåter for introduksjon av nukleinsyresekvens i målceller, fremstilling av peptid eller protein og fremstilling av variant av MVA, celle som inneholder varianten, sett for immunisering samt anvendelse av varianten. | |
| IL167844A (en) | Recombinant poxvirus comprising at least two cowpox ati promoters | |
| HK1156979A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1170772A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1171249A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1076642B (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1144700A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |